Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. [electronic resource]
Producer: 20081209Description: 1377-85 p. digitalISSN:- 1555-8576
- Angiogenesis Inhibitors -- pharmacology
- Animals
- Antineoplastic Agents -- pharmacology
- Caspase 3 -- metabolism
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Cyclophosphamide -- pharmacology
- Drug Therapy, Combination
- Enzyme Activation -- drug effects
- Everolimus
- Female
- Humans
- Immunohistochemistry
- Ki-67 Antigen -- metabolism
- Mice
- Mice, SCID
- Necrosis -- pathology
- Neovascularization, Pathologic -- drug therapy
- Random Allocation
- Sirolimus -- analogs & derivatives
- Stomach Neoplasms -- blood supply
- Tumor Burden -- drug effects
- Xenograft Model Antitumor Assays -- methods
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.